跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Retavacyl 228 - Philippines FDA Drug Approval Details
Approvals
/
Philippines FDA
/
Retavacyl 228
Approved
STANDARD
Retavacyl 228
Yeluri Formulations Pvt. Ltd.
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
3124907b3f5cc313
Company
Yeluri Formulations Pvt. Ltd.
Type
Standard
Approval Details
Approval Id
3124907b3f5cc313
Drug Approval Philippines Name
Retavacyl 228
Product Name
Retavacyl 228
Registration Number
DRP-15210-02
Brand Name
Retavacyl 228
Generic Name
Co-Amoxiclav
Dosage Form
Powder for Oral Suspension (Orange Flavor)
Dosage Strength
228.5 mg / 5 mL
Manufacturer
Yeluri Formulations Pvt. Ltd.
Importer
Medinova Pharmaceutical Inc.
Distributor
Reta Drug
Issuance Date
23 September 2024
Expiry Date
28 May 2029
Pharmacologic Category
Antibacterial (Penicillin + Beta-Lactamase Inhibitor)
Classification
Prescription Drug (Rx)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
3124907b3f5cc313
Type
Standard
Back to Philippines FDA Approvals